In a move that could significantly reshape the future of mental health treatment in the United States, President Donald Trump signed an executive order designed to accelerate access to psychedelic-based therapies. The order focuses particularly on ibogaine, a psychoactive substance derived from an African shrub that some researchers and veterans’ advocacy groups believe may help treat post-traumatic stress disorder (PTSD), depression, addiction, and other difficult mental health conditions. The decision marks one of the most dramatic shifts in federal drug policy in recent years. Psychedelic substances have long been controversial in the United States, where many remain classified as illegal drugs with no accepted medical use. Yet growing scientific interest, combined with pressure from veterans and bipartisan lawmakers, has pushed the topic from the margins of public debate into the center of national policy discussions.
Under the new order, the U.S. Food and Drug Administration is instructed to expedite the review of treatments involving psychedelic compounds, including ibogaine. Federal officials said the administration’s reforms could pave the way for these substances to be reclassified if ongoing and future clinical trials confirm their safety and effectiveness. Trump also announced $50 million in new federal funding for ibogaine research. That investment signals the administration’s intention not merely to debate psychedelic medicine, but to actively accelerate its scientific development.
Ibogaine is extracted from the root bark of the iboga shrub, native to Central and West Africa, where it has historically been used in spiritual and ceremonial contexts. In the United States, however, the substance is classified as Schedule I under federal law—a category reserved for drugs considered to have a high potential for abuse and no accepted medical use. That classification has made large-scale medical research difficult for decades.
Supporters argue that the designation is outdated. Some small studies and anecdotal reports suggest ibogaine may help reduce symptoms of trauma, interrupt addiction patterns, and improve emotional regulation. Veterans’ groups have become especially vocal advocates, saying conventional treatments for PTSD often fail many former service members.
At the White House signing ceremony, Trump was joined by military veterans including Marcus Luttrell and Congressman Morgan Luttrell of Texas. Also present was podcaster Joe Rogan, whose widely followed show has featured advocates of psychedelic therapies and helped bring ibogaine into mainstream political conversation.
Trump acknowledged that Rogan’s discussions played a role in introducing him to the issue. “I’ve been hearing about it a little bit over the last year,” the president said. “It was almost taboo. It’s not taboo anymore. That statement reflects a broader cultural transformation. For decades, psychedelics were associated primarily with counterculture movements and criminal enforcement. Today, they are increasingly studied at major universities and discussed by doctors, investors, policymakers, and patients searching for alternatives to traditional psychiatric medications.
Health Secretary Robert F. Kennedy Jr. has been one of the most prominent advocates inside the administration for exploring psychedelic medicine. He has argued that conventional pharmaceutical approaches do not work for everyone and that innovative therapies deserve serious scientific evaluation rather than stigma. FDA Commissioner Marty Makary suggested decisions on some psychedelic-related treatments could come as soon as this summer, indicating a potentially rapid regulatory timeline. Still, enthusiasm is accompanied by caution. Psychedelic substances can cause hallucinations, altered perception, emotional intensity, and medical complications if improperly used. Experts stress that any therapeutic use must occur in controlled clinical settings with professional supervision. Ibogaine in particular has been linked in some cases to serious cardiac risks, making medical screening essential.
Another important factor is the international dimension of treatment access. Because ibogaine remains illegal in the United States, some Americans—especially veterans—have traveled to Mexico, where treatment centers legally offer ibogaine therapies under looser regulations. These clinics have become destinations for people frustrated by limited domestic options.
Trump’s order may reduce the need for such medical tourism if research progresses and regulated treatment pathways open inside the United States. The initiative also reveals unusual bipartisan alignment. While drug policy often divides American politics, psychedelic reform has supporters across ideological lines. Some conservatives see it as a practical tool to help veterans and reduce dependence on opioids or antidepressants. Some liberals support it as criminal justice reform and expanded healthcare innovation.
Democratic Congressman Lou Correa praised the move publicly, saying that if ibogaine appears promising, the government should allow more studies by removing barriers created by Schedule I classification.
This is not Trump’s first step in this area. In December, he signed another executive order supporting research into marijuana and cannabidiol (CBD), while urging movement toward cannabis reclassification. However, executive orders can only go so far. Durable legal reform usually requires congressional action or regulatory changes from agencies such as the Drug Enforcement Administration.
That means Saturday’s announcement may be the beginning rather than the end of a long policy battle.
Critics are likely to question whether the administration is moving too quickly or relying too heavily on anecdotal success stories. Others will ask whether hype is getting ahead of evidence. Those are legitimate concerns in any emerging medical field.
Yet supporters counter that mental health systems are already failing millions of people, especially veterans facing trauma, addiction, and suicide risk. In their view, refusing to study potentially life-changing treatments would be the greater mistake.
Comments